E

Molecular Jiu-Jitsu – Turning Cancer’s Mistakes Against Itself

Our 7th AACR Preview takes stock of an emerging class of anti-cancer agents

March 18, 2024
E

An unexpected surprise!

In our fifth preview from the AACR annual meeting being held in San Diego next month, we noticed some…

March 12, 2024
E

Pointing the way in AML

It's time to start pointing the way for new directions in the Menin niche

January 30, 2024
E

An up and coming biotech not at JPM

Next generation CAR-T cells are coming to the clinic in 2024

January 8, 2024
E

An emerging new target for ER positive breast cancer

Hats off to companies pursuing an emerging target in breast cancer

December 19, 2023
E

Breathing fire into targeted therapies at ASH23

In our latest Preview from the American Society of Hematology, we’re using the dragon’s…

November 30, 2023
E

Seeing the wood from the trees at ASH23

How a competitive landscape can change drastically over a short time

November 27, 2023
E

Precision Targeting of Elusive Cancer Oncogenes

More gems from the TARGETS23 poster halls

October 16, 2023
E

What to watch out for at TARGETS23 – Part 2

What to watch out for in DDR, epigenetic therapies, and other hot topics

October 11, 2023
E

Ever Decreasing Circles

From epigenetics to SHP2, a look at various upcoming presentations this month

October 5, 2023
E

Early stage oncology data of interest in TARGETS23 preview

A look at some hot topics from the TARGETS/TRIPLE meeting in Boston

September 20, 2023
E

What science tells us about future directions in lung cancer

What we can learn from scientific talks at WCLC in order to improve clinical development

September 13, 2023
E

The scudding clouds of freedom

Finding the sweetspot in early stage cancer drug development

August 16, 2023
E

Cracking the Code on a Novel Cancer Target

One of the challenging and frustrating aspects of oncology drug development is in knowing a target is…

August 10, 2023
E

Summer fun with AI

How we can use AI to improve scientific writing and reports

July 13, 2023
E

Cut and run

A potentially novel approach for some advanced breast cancers

July 11, 2023
E

An under-rated gem at ASCO23

Tackling intractable cancers with a novel and creative approach to the problem

June 8, 2023
E

A look at early stage trials debuting at ASCO23

What do three phase 1 and one phase 2 trials tell us about future development?

June 5, 2023
E

Early research which points us to new cancer therapeutic opportunities

Have you ever wondered why some anti-cancer agents do well and others poorly – even with similar…

May 11, 2023
E

The road less travelled

Off the beaten track can bring danger and delight in the unknown in equal measure

May 2, 2023
E

ASCO23 Preview 1 – W2W4 in Developmental Therapeutics

Update on Developmental Therapeutics

April 27, 2023
E

AACR23 Insights on gems from the poster halls – Part 1

Where we explain what to look for in 10 posters presented at AACR23

April 25, 2023
E
The key to success in TPD

AACR23 Preview 8 – Keys to success in TPD

W2W4 on the TPD front

April 14, 2023
E

AACR23 Preview 6 – Taking a closer look at KRAS Part 1

The ever evolving selective KRAS inhibitor & degrader space

March 29, 2023
E

AACR23 Preview 5 – an emerging landscape

A look at an emerging early stage oncology landscape

March 23, 2023
E

AACR23 Preview 4 – Stepping It Up

Continuing our evaluation and exploration of another batch of early stage anti-cancer compounds either…

March 20, 2023
E

Cracking the code to the MYC oncogene

A novel approach to targeting an intractable oncogene

January 23, 2023
E

Moving targets

Ten emerging development areas to watch out for in oncology during 2023

January 5, 2023
E

On the prickly issues facing the Menin inhibitors

Some key subtleties and nuances to watch out for in the Menin niche

December 13, 2022
E

Tilting at windmills

The importance of T cell exhaustion and exploring ways to avoid it

December 5, 2022
E

Dancing with Cancer Cells

The beat goes on for synthetic lethal approaches

November 17, 2022
E

On overcoming resistance to protein degraders

Are there opportunities for combining small molecule inhibitors with protein degraders?

October 19, 2022
E

SITC22 Preview 1 – Looking under the hood

6 abstracts to watch out for on how to overcome immune escape

October 12, 2022
E

New directions and opportunities with intractable oncology targets

Just because a pathway has been called undruggable doesn't always mean it will be so!

March 15, 2022
E

A fine line between failure and success

9 hidden Gems from the ASH21 poster hall and why you should pay attention to them

December 17, 2021
E

Targeting Menin and the evolving landscape for NPM1-MLLr acute leukemias

A look at new data in the Menin/MLLr inhibitor landscape in acute leukemias

April 20, 2021
E

5 early developments to watch out for at AACR21

What's hot in early preclinical development to watch out for?

April 5, 2021
E

AACR21 Preview 3 Novel and cool approaches emerging in oncology pipelines

Emerging areas in cool new science around targeted therapies

March 18, 2021
E

ASH Day 1 highlights and lowlights Part 2

Highlights on translational research and clinical trials in AML and BCLA CAR T cell therapy

December 6, 2020
E

Bigging up targeted therapies at ASH 2020

W2W4 in targeted therapies at ASH20 - some key early stage areas to focus on

December 4, 2020
E

A new dawn for epigenetic therapy in oncology

A novel epigenetic target may have far-reaching outcomes for cancer patients

July 23, 2020
E

Standing out from the crowd

One particular presentation stood out from the others at AACR20 this year

April 29, 2020
E

Postcards from Day 1 of AACR20

Commentary on Day 1 of the AACR20 Virtual Meeting

April 28, 2020
E

AACR20 – Ten New Directions in Early Cancer Drug Development

Ten intriguing novel agents in early development to watch out for

April 23, 2020
E

AACR Preview 2 – Pathways to Success in Targeted Therapies

A look at a wide array of targets, modalities, new agents and companies through the lens of targeted therapies

April 16, 2020
E

Novel Targets and Agents – Part 2

In the first part of the review on novel targets in hematologic malignancies, we covered five key areas…

March 20, 2020
E

Will 2020 be an inflection year for Kura Oncology?

Update on Kura Oncology's progress with tipifarnib and their emerging pipeline

January 16, 2020
E

ESMO19 Day 3 Highlights and Commentary

Key findings and commentary on the third day of ESMO

September 29, 2019
E

On the interaction between transcription factors and the immune system

A potential role for epigenetic therapies in straddling the divide between transcription factors and the immune system...

August 26, 2019
E

ASH Preview 2 – Developmental Therapeutics

A look at a selection of promising Developmental Therapeutics abstracts from ASH17 - what's in store this year?

November 29, 2017
E

Can we target p53 therapeutically?

What's new about p53 mutants and MDM2 inhibitors?

February 7, 2019
E

Can entinostat overcome resistance to pembrolizumab?

A look st Syndax's entinostat and what happens when given in combination with pembrolizumab in melanoma and lung cancer

November 14, 2017
E

Things we need to think about ahead of ASCO17

A fireside chat with a leading KOL involved in cancer research on resistance.

May 16, 2017
E

AACR 2017 Preview 3

After exploring a mechanistic approach and a tumour type as part of our AACR annual meeting coverage, in…

March 8, 2017
E

Novel Targets in Multiple Myeloma

Going beyond proteasome inhibitors and IMiDs in multiple myeloma - what novel targets are attractive?

February 8, 2017
E

Novel targets and approaches in triple negative breast cancer

What are the new targets and drug combinations that are emerging in triple negative breast cancer (TNBC)? find out more about the promising developments in this field.

April 1, 2014